4.8 Article

Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells

Journal

NATURE COMMUNICATIONS
Volume 7, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms11626

Keywords

-

Funding

  1. Deutsche Forschungsgemeinschaft, DFG [GO 2505/1-1, ME3283/5-1, ME3283/6-1, KFO274]
  2. EKFS [2015_A113]
  3. Medical Faculty Munster
  4. IMF [GO 1 1 14 01]
  5. CIM
  6. Volkswagen Foundation (Lichtenberg Program)
  7. Biogen Idec GmbH, Ismaning, Germany
  8. Novartis Pharma GmbH, Nurnberg, Germany
  9. [SFB 688]
  10. [SFB (TRR 128/1 2012 TP B06)]

Ask authors/readers for more resources

Aberrant immune responses represent the underlying cause of central nervous system (CNS) autoimmunity, including multiple sclerosis (MS). Recent evidence implicated the crosstalk between coagulation and immunity in CNS autoimmunity. Here we identify coagulation factor XII (FXII), the initiator of the intrinsic coagulation cascade and the kallikrein-kinin system, as a specific immune cell modulator. High levels of FXII activity are present in the plasma of MS patients during relapse. Deficiency or pharmacologic blockade of FXII renders mice less susceptible to experimental autoimmune encephalomyelitis (a model of MS) and is accompanied by reduced numbers of interleukin-17A-producing T cells. Immune activation by FXII is mediated by dendritic cells in a CD87-dependent manner and involves alterations in intracellular cyclic AMP formation. Our study demonstrates that a member of the plasmatic coagulation cascade is a key mediator of autoimmunity. FXII inhibition may provide a strategy to combat MS and other immune-related disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available